Other Name(s): C-Myc, C-myc, Myc
Assay:Inhibition of recombinant His6-tagged c-Myc bHLH-ZIP domain (353 to 437 amino acid residues) (unknown origin) assessed as disruption of Myc-Max dimerization by electrophoretic mobility shift assay
Type:IC50
SMILES:O=C(O)c1ccc(Nc2ccc([N+](=O)[O-])c3nonc23)cc1
Value:=33000nM
Source:Homo sapiens
Assay:Inhibition of recombinant His6-tagged c-Myc bHLH-ZIP domain (353 to 437 amino acid residues) (unknown origin) assessed as disruption of Myc-Max dimerization by electrophoretic mobility shift assay
Type:IC50
SMILES:O=[N+]([O-])c1ccc(Nc2ccccc2-c2ccccc2)c2nonc12
Value:=146000nM
Source:Homo sapiens
Assay:Binding affinity to human c-Myc bHLH-ZIP domain (353 to 437 amino acid residues) expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay
Type:Kd
SMILES:O=[N+]([O-])c1ccc(Nc2ccccc2-c2ccccc2)c2nonc12
Value:=2800nM
Source:Homo sapiens
Assay:Inhibition of Myc signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
Type:IC50
SMILES:Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Value:=60000nM
Source:Homo sapiens
Assay:Inhibition of Myc signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction
Type:IC50
SMILES:COc1cc(/C=C\c2ccc(OC)c(OC)c2)cc(OC)c1
Value:=60000nM
Source:Homo sapiens
Assay:Inhibition of c-MYC in human HL60 cells by chemiluminescence assay
Type:IC50
SMILES:CC(C)c1ccc(/C=C2\SC(=S)N(CN3CCCCC3)C2=O)cc1
Value:=29000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=[N+]([O-])c1ccc(Nc2ccccc2-c2ccccc2)c2nonc12
Value:=2800nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:CCc1ccc(/C=C2\SC(=S)NC2=O)cc1
Value:=5700nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=[N+]([O-])c1ccc(Nc2ccccc2)c2nonc12
Value:=7000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:CN(C)c1ccc([N+](=O)[O-])c2nonc12
Value:>200000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=C(O)c1ccccc1Nc1ccc([N+](=O)[O-])c2nonc12
Value:=13000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=C(O)c1cccc(Nc2ccc([N+](=O)[O-])c3nonc23)c1
Value:=16000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=C(O)c1ccc(Nc2ccc([N+](=O)[O-])c3nonc23)cc1
Value:=3000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:CC(=O)NCCCCCOC(=O)c1ccc(Nc2ccc([N+](=O)[O-])c3nonc23)cc1
Value:=1700nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=C1NC(=S)S/C1=C\c1ccc(C(=O)O)cc1
Value:=26000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:CC(=O)NCCCCCNC(=O)c1ccc(/C=C2\SC(=S)NC2=O)cc1
Value:=90000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:CCc1ccc(/C=C2\SC(=O)N(CCCCCCNC(C)=O)C2=O)cc1
Value:=7000nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=C1NC(=S)S/C1=C\c1ccc(C(=O)NCCCCCNC(=O)c2ccccc2Nc2ccc([N+](=O)[O-])c3nonc23)cc1
Value:=24nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:O=C1NC(=S)S/C1=C/c1ccc(C(=O)NCCCCCNC(=O)c2ccc(Nc3ccc([N+](=O)[O-])c4nonc34)cc2)cc1
Value:=4.7nM
Source:Homo sapiens
Assay:Binding affinity to recombinant full-length N-terminal hexahistidine-tagged c-Myc (353 to 437 residues) bHLH-ZIP domain (unknown origin) expressed in Escherichia coli BL21 DE3 (pLysS) by fluorescence polarization assay
Type:Kd
SMILES:CCc1ccc(/C=C2\SC(=O)N(CCCCCNC(=O)c3ccccc3Nc3ccc([N+](=O)[O-])c4nonc34)C2=O)cc1
Value:=2.2nM
Source:Homo sapiens

Note: If you'd like to learn how our AI-powered BDE-Chem can help design therapeutic molecules against the MYC target, that break through the existing patents, at a cost 90% lower than traditional approaches, please feel free to contact us at BD@silexon.ai

Molecules for More Common Targets

ABCB1 | ABCG2 | ACE2 | AHR | AKT1 | ALK | AR | ATM | BAX | BCL2 | BCL2L1 | BRAF | BRCA1 | CASP3 | CASP9 | CCL5 | CCND1 | CD274 | CD4 | CDKN1A | CXCL8 | CXCR4 | DNMT1 | EGF | EGFR | EP300 | ERBB2 | ESR1 | EZH2 | FN1 | FOXO3 | HDAC9 | HGF | HMGB1 | HSP90AA1 | HSPA5 | IDO1 | IGF1 | IGF1R | IL17A | IL6 | INS | JUN | KRAS | MAPK1 | MAPK14 | MAPK3 | MAPK8 | MAPT | MCL1 | MMP9 | MTOR | MYC | NFE2L2 | NLRP3 | NOTCH1 | PARP1 | PCNA | PDCD1 | PLK1 | PRKAA1 | PRKAA2 | PTEN | PTGS2 | PTK2 | RELA | SIRT1 | SRC | STAT1 | STAT3 | STAT5A | TERT | TLR4 | TNF | TP53 | TXN | VEGFA | YAP1